S&P Futures
3,755.25 -34.25 (-0.90%) Dow Futures
30,527.00 -254.00 (-0.83%) Nasdaq Futures
11,420.00 -109.50 (-0.95%) Russell 2000 Futures
1,686.10 -21.90 (-1.28%) Crude Oil
105.67 -0.09 (-0.09%) Gold
1,801.60 -5.70 (-0.32%)
Emergent BioSolutions Inc. (EBS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 30.53 |
| Open | 30.40 |
| Bid | 29.49 x 1100 |
| Ask | 32.44 x 1000 |
| Day's Range | 30.11 - 31.81 |
| 52 Week Range | 26.85 - 68.03 |
| Volume | |
| Avg. Volume | 762,703 |
| Market Cap | 1.56B |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | 11.13 |
| EPS (TTM) | 2.79 |
| Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.33 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for EBS
Related Research
- Emergent Biosolutions, Inc.Analyst Report: Emergent BioSolutions IncEmergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses), as well as from contract development and manufacturing services and contracts and grants. The USG is the company's primary customer, and provides EBS with significant product development funding. EBS shares are a component of the S&P 400 Index. The company has approximately 2,500 employees.RatingFair ValueEconomic Moat4 months agoArgus Research
- Barrons.com
White House Expands Monkeypox-Vaccination Campaign
The White House will sharply expand availability of monkeypox vaccines while rolling out more testing capacity for the virus.
- Zacks
Emergent's (EBS) Anthrax Vaccine BLA Gets FDA Acceptance
The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.
- MarketWatch
UPDATE: Emergent BioSolutions says FDA has accepted its anthrax vaccine candidate for review
Emergent BioSolutions Inc. said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax vaccine. Dubbed AV7909, the vaccine is aimed at people aged 18 through 65 years who have been exposed to anthrax for use along with recommended antibacterial drugs. A decision is expected by April of 2023. "As we progress toward licensure of AV7909, which is designed to follow a two-dose immunization schedule and to elicit a faster immune response, we r
